CA3229203A1 - Therapeutic papilloma virus vaccines - Google Patents

Therapeutic papilloma virus vaccines Download PDF

Info

Publication number
CA3229203A1
CA3229203A1 CA3229203A CA3229203A CA3229203A1 CA 3229203 A1 CA3229203 A1 CA 3229203A1 CA 3229203 A CA3229203 A CA 3229203A CA 3229203 A CA3229203 A CA 3229203A CA 3229203 A1 CA3229203 A1 CA 3229203A1
Authority
CA
Canada
Prior art keywords
nucleic acid
cells
cell
vector
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3229203A
Other languages
English (en)
French (fr)
Inventor
Christian Thirion
Cordula Pertl
Alexander Karlas
Volker Sandig
Ingo Jordan
Peter Johannes Holst
Ditte Rahbæk Boilesen
Ralf Wagner
Patrik Neckermann
Benedikt ASBACH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProBioGen AG
University of Regensburg
Sirion Biotech GmbH
InProTher ApS
Original Assignee
ProBioGen AG
University of Regensburg
Sirion Biotech GmbH
InProTher ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProBioGen AG, University of Regensburg, Sirion Biotech GmbH, InProTher ApS filed Critical ProBioGen AG
Publication of CA3229203A1 publication Critical patent/CA3229203A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3229203A 2021-08-18 2022-08-17 Therapeutic papilloma virus vaccines Pending CA3229203A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21191940.2 2021-08-18
EP21191940.2A EP4137153A1 (en) 2021-08-18 2021-08-18 Therapeutic papilloma virus vaccines
PCT/EP2022/073016 WO2023021116A1 (en) 2021-08-18 2022-08-17 Therapeutic papilloma virus vaccines

Publications (1)

Publication Number Publication Date
CA3229203A1 true CA3229203A1 (en) 2023-02-23

Family

ID=77398487

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3229203A Pending CA3229203A1 (en) 2021-08-18 2022-08-17 Therapeutic papilloma virus vaccines

Country Status (9)

Country Link
US (1) US20250066427A1 (enExample)
EP (2) EP4137153A1 (enExample)
JP (1) JP2024532853A (enExample)
KR (1) KR20240095168A (enExample)
CN (1) CN117940156A (enExample)
AU (1) AU2022331111A1 (enExample)
CA (1) CA3229203A1 (enExample)
MX (1) MX2024002010A (enExample)
WO (1) WO2023021116A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026523389A (ja) * 2023-05-26 2026-07-14 プロバイオジェン アーゲー 二倍体組換え核細胞質大型ｄｎａウイルスベクター
CN120607593A (zh) * 2024-03-06 2025-09-09 诺未生物技术(无锡)有限公司 治疗hpv感染相关疾病的药物
CN119569831B (zh) * 2024-12-13 2026-04-28 深圳锦时生物科技有限公司 一种活性多肽及在预防和/或治疗hpv中的应用
CN122405672A (zh) * 2025-01-10 2026-07-17 成都迈科康生物科技股份有限公司 一种rna疫苗及其相关产品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
EP1427443A4 (en) * 2001-08-23 2006-03-08 Merck & Co Inc VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR
SI1957528T1 (sl) 2005-11-30 2013-02-28 University Of Copenhagen Nukleotidno cepivo
SI2865387T1 (sl) 2008-11-21 2019-10-30 Kobenhavns Univ University Of Copenhagen Primiranje imunskega odziva
GB201321384D0 (en) 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
EP3452087A1 (en) * 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
WO2018060288A1 (en) * 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201704417D0 (en) 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
US12576143B2 (en) 2018-10-19 2026-03-17 Nouscom Ag Teleost invariant chain cancer vaccine

Also Published As

Publication number Publication date
MX2024002010A (es) 2024-04-18
EP4387662A1 (en) 2024-06-26
EP4137153A1 (en) 2023-02-22
AU2022331111A1 (en) 2024-03-07
WO2023021116A1 (en) 2023-02-23
US20250066427A1 (en) 2025-02-27
KR20240095168A (ko) 2024-06-25
JP2024532853A (ja) 2024-09-10
CN117940156A (zh) 2024-04-26

Similar Documents

Publication Publication Date Title
AU2021232660B2 (en) HPV vaccines
US20250066427A1 (en) Therapeutic papilloma virus vaccines
JP6606571B2 (ja) 治療用ｈｐｖ１６ワクチン
He et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16
US11466292B2 (en) Compositions and methods of treatment
JP2019068852A (ja) 治療用ｈｐｖ１８ワクチン
Massa et al. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein
Boilesen et al. Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome–Positive C3 Cancers in Mice
EP1195438A1 (en) Genetic immunisation against cervical carcinoma
Neckermann et al. Design and immunological validation of macaca fascicularis papillomavirus type 3 based vaccine candidates in outbred mice: basis for future testing of a therapeutic papillomavirus vaccine in NHPs
CN119894530A (zh) 用于表达人乳头瘤病毒(hpv)抗原的慢病毒载体及其在治疗hpv诱发的癌症中的应用
Neckermann Design and Characterization of Vaccine Candidates for Therapeutic Vaccination Against Papillomaviruses
US20250041399A1 (en) Cmv-based human papillomavirus vaccines
Illiano et al. Prime–boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the human papilloma virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X
CN118354790A (zh) 用于表达人乳头瘤病毒(hpv)抗原的慢病毒载体及其在治疗hpv诱发癌症中的应用
Liao Studies of therapeutic vaccination and immune evasion by human papillomavirus oncoproteins
Poláková Gene Immunotherapy of Cancer: DNA Vaccines against HPV 16

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240729

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808